Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous disease with a highly variable clinical course. Staging systems devised by Rai 1 and Binet 2 are useful for predicting survival and treatment requirements in patients with CLL. However, these staging systems are of limited prognostic value in early stages of the disease (Binet A or Rai stages 0-II), which applies for most of the patients at first diagnosis. Therefore, a number of studies aimed at identifying novel prognostic markers, which may help define patient subgroups with favorable vs poor clinical outcome in early CLL. 3 The presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgVH) of B-CLL cells has been described as one of the most powerful prognostic factors, as B-CLL cases with mutated IgVH genes exhibit a favorable clinical course while B-CLL patients with unmutated Ig VH genes are characterized by a poor outcome in terms of reduced survival and responsiveness to chemotherapy. [4] [5] [6] [7] [8] Recently, Rosenwald et al 9 demonstrated that expression analysis of a single gene, the protein tyrosine kinase ZAP-70, could correctly predict the IgVH mutation status in 93% of patients. We could confirm previous studies by showing that ZAP-70 expression is a novel prognostic marker in B-CLL. Furthermore, our results and those of others suggest that a combination of prognostic factors such as ZAP-70 plus CD38 expression status may help optimize currently available prognostic instruments for the risk stratification of CLL patients in clinical trials. 10 A refined risk stratification of CLL patients, especially for those patients in stage A according to Binet, may in future guide more specific, tailored treatment decisions for an individual patient.
Common single-nucleotide polymorphisms (SNPs) in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (677C4T and 1298A4C) have been associated with the risk for adult and childhood acute lymphocytic leukemia. [11] [12] [13] The enzyme MTHFR catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the carbon donor for de novo methionine synthesis and DNA methylation. Approximately 10% of Caucasian populations are homozygous for a common C4T substitution at nucleotide 677 of the MTHFR gene. This mutation converts an alanine to a valine at codon 225 and is associated with reduced enzyme activity. The potential influence of MTHFR activity on DNA methylation and on the availability of uridylates and thymidylates for DNA synthesis and repair makes the MTHFR an attractive candidate for a cancer predisposing gene. [14] [15] [16] Recently, a second common polymorphism in the MTHFR gene has been reported that results in a glutamate to alanine (A4C) change at position 1298, which also leads to diminished enzyme activity. Frequencies of up to 33% have been reported previously for the 1298C allele. 17, 18 The association of MTHFR variants with an increased or decreased risk for different neoplasia was reported in several studies. Homozygous 677T allele carriers may have a reduced incidence of colorectal cancer that can be further modified by dietary habits and life style. 19, 20 In contrast, an increased frequency of 677T homozygotes was observed in cervical intraepithelial neoplasia, 21, 22 esophageal, 23 endometrial, 24 stomach, 25 lung cancer 26, 27 as well as breast carcinoma.
28,29
Here, we report a single-center retrospective study of 111 CLL patients designed to evaluate the potential of the MTHFR 677C4T and 1298A4C gene polymorphisms as a prognostic factor for the natural course of B-CLL in patients with Binet stage A. In addition, we report the results of a multivariate analysis of the genotype data with other important prognostic factors in B-CLL. Finally, we investigated which cellular phenotype might contribute to the observed association.
Materials and methods

Patients
Between August 2001 and October 2003, 111 samples of Caucasian patients with CLL were enrolled in this retrospective study and analyzed for several biological and clinical characteristics including age, gender, Binet stage, white blood cell count, hemoglobin concentration, platelet count, lactate dehydrogenase, thymidine kinase, treatment history and time from diagnosis to first treatment. In each patient, morphologic diagnosis of B-CLL was confirmed by flow cytometry 8, 30 revealing a typical CD19 þ , CD20 þ , CD5 þ , CD23 þ , Ig light chain (k or l light chain) restricted immunophenotype. ZAP-70 and CD38 expression was confirmed by flow cytometry as described. 8, 10 Whole peripheral blood samples were usually obtained during routine follow-up visits to our institutions with all patients giving informed consent according to institutional guidelines. Indications for treatment were based on standard criteria. 31 Out of a total of 111 patients, 53 (47%) had previously received chemotherapy, and almost 34 patients of the 53 CLL (64%) patients received a second therapy. In first-line therapy, 36 patients received chlorambucil, 14 patients fludarabine and three patients the CHOP regime. In Table 1 , the clinical and laboratory data are shown. As control, DNA from 92 agematched healthy blood donors recruited at our local transfusion center was analyzed.
Determination of the MTHFR 677 and 1298 genotypes
Genomic DNA was extracted using the QIAamp blood kit (Qiagen, Hilden, Germany) following the manufacturer's instructions and MTHFR genotypes were determined by PCR-RFLP as described. 12, 28 Isolation and culture of cells Mononuclear cells were isolated from 21 patients with B-CLL by centrifugation of whole blood on a Ficoll/Hypaque gradient and cryopreserved in liquid nitrogen. Freezing/thawing did not influence the cell response (three patients, data not shown). Lymphocytes were cultured for 24 h at a cell concentration of 2.5 Â 10 6 /ml in Iscove's modified Dulbecco's (GIBCOt, Germany) culture medium supplemented with 15% heat-inactivated fetal calf serum, 1% penicillin and streptomycin at 371C in a humidified atmosphere containing 5% carbon dioxide.
Analysis of cell viability by Annexin V binding
To quantitate apoptosis, cells were harvested, washed twice in phosphate-buffered saline (PBS), gently resuspended into 0.4 ml binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl), and incubated with 0.5 mg/ml Annexin Vfluorescein isothiocyanate and 10 ml propidium iodide (PI) for 15 min in the dark (Apoptosis Detection Kit I, BD-Pharmingen, Germany) according to the manufacturer's instructions. There were 10 000 events acquired on a FACSort flow cytometer and analyzed by means of the CellQuest software. Apoptotic cells were defined as cells expressing Annexin-V (PI positive and PI negative).
Statistical analysis
Progression-free survival times were measured from the first time of diagnosis, plotted by the Kaplan-Meier method and compared using the log-rank test. Comparison of clinical and laboratory parameters between patient subgroups was performed using Student's t-test for continuous variables and the w 2 test for categorical data. Comparison of apoptosis rates dependent on genotypes was performed using the ANOVA and Mann-Whitney test, respectively. Differences were regarded significant at Po0.05.
To study the impact of prognostic factors for a first-line therapy, a multivariate Cox regression analysis was performed. The results were analyzed using SPSS for Windows s 11.0 (SPSS, Chicago, IL, USA).
Haplotype analysis and control for deviation from the HardyWeinberg equilibrium (HWE) were conducted with the public domain programs EH and HWE by J Ott (http://linkage. rockefeller.edu/ott/linkutil.htm).
Results
MTHFR 677C4T and MTHFR 1298A4C genotype distributions in cases and controls
We analyzed 111 patients with CLL and 92 age-matched controls for the MTHFR 677C4T and MTHFR 1298A4C gene polymorphisms ( Table 1 ). The distribution of the MTHFR 677 and 1298 genotypes and the allele frequency are shown in Table 2 . Thus, we found no association of MTHFR 677 and 1298 genotypes with CLL risk. The observed genotype distributions in CLL patients and in healthy controls for MTHFR 677 and 1298 were in perfect accordance with HWE.
Correlation of MTHFR 677C4T polymorphism with clinical and laboratory data in CLL patients
Within a median follow-up of 34 months (range 0-259), 52 patients (47%) required first-line chemotherapy. In the group of patients with MTHFR 677CC genotype 25 patients (48%), in the heterozygous group 22 patients (42%) and in the group of patients with MTHFR 677TT genotype five patients (10%) received chemotherapy. A comparison of clinical and laboratory parameters among these groups by genotype is shown in Table 1 . Time from diagnosis to initiation of chemotherapy was genotype independent in the whole group of individuals with CLL, including all Binet stages (P ¼ 0.25, data not shown) and for the combined 677CT plus TT genotypes vs the 677CC genotype (P ¼ 0.55, data not shown).
However, in CLL patients with stage A according to Binet, we found MTHFR 677 genotype-associated differences in disease progression as indicated by different treatment-free intervals. Comparing all three genotypes, patients with 677CC genotypes have a longer progression-free survival than those with 677CT or TT, although the P-value is not significant (P ¼ 0.13, data not shown). In a subsequent analysis, we combined the MTHFR 677TT and TC genotypes and compared them with CC genotypes. This appears justified as the 677T allele is associated with reduced MTHFR activity compared to the CC genotype. 32 The median treatment-free interval was significantly longer in the patients with the MTHFR 677CC genotype (152 months) compared to the patient cohort with MTHFR 677CT or TT (96 months, P ¼ 0.04; Figure 1a ).
Correlation of MTHFR 1298A4C gene polymorphism with clinical and laboratory data in CLL patients
In patients with MTHFR 1298AA genotype 26 patients (50%), in the heterozygous group 19 patients (37%) and in the group of patients with MTHFR 1298CC genotype seven patients (13%) received chemotherapy. A comparison of additional clinical and laboratory parameters by genotype is shown in Table 1 and yielded no significant differences. Time from diagnosis to initiation of chemotherapy was not significantly different in individuals with CLL, including all stages, displaying the three genotypes (P ¼ 0.32, data not shown) and for the combined 1298AC and CC genotypes vs the 1298AA genotype (P ¼ 0.17, data not shown).
However, in CLL patients with stage A according to Binet, we observed significant differences in disease progression, as indicated by the treatment-free interval. This was evident on comparison of all three MTHFR 1298 genotypes (P ¼ 0.04, data not shown) as well as in the combined group of MTHFR 1298AC plus CC genotypes vs MTHFR 1298AA genotypes (Figure 1b , P ¼ 0.02). The median treatment-free interval was almost 2.5 times longer in patients with the MTHFR 1298AC or CC genotypes (173 months) compared to patients with MTHFR 1298AA genotype (67 months, P ¼ 0.02; Figure 1b ).
Haplotype analysis of MTHFR 677C4T and MTHFR 1298A4C gene polymorphism
Previous studies reported for this pair of loci a strong linkage disequilibrium. 33 The prevailing haplotypes and their frequencies in controls and CLL patients are displayed in Table 2 . The P-value for the linkage disequilibrium was highly significant (Po0.0001, D (mean7s.d.) ¼ 0.09670.0001; D' (mean7 s.d.) ¼ 1.070.0000) in both cohorts. Comparing the three haplotypes with regard to disease progression in CLL patients with stage A according to Binet, we observed a longer median treatment-free interval in the patients carrying the C allele of both polymorphisms (173 months) compared to patients with the MTHFR 677T allele and 1298A allele (96 months) or the MTHFR 677C allele and 1298A allele (96 months, P ¼ 0.13, data not shown).
Next we compared the impact of the specific haplotypes associated either with prolonged treatment-free survival (C allele at positions 677 and 1298) or with enhanced progression (677T allele and 1298A allele). The median progression-free survival was just not significantly different (P ¼ 0.053). Notably, in these groups, those patients who are heterozygous for both respective polymorphisms remain included. Therefore, in the next step, we compared the course of the disease in those patients who are heterozygous for both polymorphisms (MTHFR 677CT genotype plus 1298AC genotype) with those patients with MTHFR 677CC genotype plus 1298CC or AC genotype and those with 677T allele (CT or TT genotype) plus 1298AA genotype. As expected, the course of the heterozygous group was in between the two other groups with significant differences in the progression-free survival over all three groups (P ¼ 0.043, Figure 2) .
Because of the better discrimination of the two groups without the heterozygous group (borderline group), we combined these for analysis of a favorable risk group with the genotypes 1298AC plus CC and 677CC and an unfavorable risk group with the genotypes 1298AA and 677CT plus TT. A comparison of clinical and laboratory parameters among these defined groups showed no significant differences concerning other prognostic factors (data not shown).
Comparing the two genotype groups with regard to their clinical characteristics in CLL patients with stage A according to Binet, we observed significant differences in disease progression, as indicated by the treatment-free interval. The median treatment-free interval was significantly longer in the patients 
Multivariate (Cox) analysis for independent prognostic factors
Subsequently, we investigated the potential utility of the MTHFR polymorphisms as independent prognostic factors. The following variables were included in these analysis: gender, age (o60 years), ZAP-70 status, CD38 status, the MTHFR 677 genotypes, the MTHFR 1298 genotypes and a combination of both MTHFR polymorphisms. Analyses were conducted for patients in stage A according to Binet. The predictive power of the MTHFR genotypes was analyzed by Cox's proportional models at different levels of data adjustment (Table 3) Both MTHFR polymorphisms are independent factors if only adjusted for gender and age. To demonstrate that the genotypes are independent markers in combination with other known prognostic markers, we analyzed the genotypes together with the CD38 and ZAP-70 status, respectively.
The 677T allele (TT and TC genotypes) is also an independent prognostic marker (P ¼ 0.018) together with ZAP-70 status compared with the other variables. Moreover, compared with CD38 status, these genotypes may be more informative prognostic markers (P ¼ 0.065). For the MTHFR 1298A4C polymorphism, the AA genotype alone is the best prognostic marker compared with CD38 status (P ¼ 0.03), and compared with ZAP-70 status the MTHFR 1298AA genotype just escaped statistical significance (P ¼ 0.06). The haplotype consisting of MTHFR 1298AA plus MTHFR 677TT or CT genotype is the only independent factor compared with CD38 status or ZAP-70 status ( Table 3 ). Assuming that the combination of ZAP-70 and CD38 may increase their prognostic power, we composed a subgroup with favorable prognostic markers (ZAP-70-and CD38-negative patients) and a subgroup with unfavorable prognostic markers (ZAP-70-and CD38-positive patients). Even upon this stratification, the 1298AA-677TT/TC haplotype is of borderline significance (P ¼ 0.075) as an independent prognostic marker ( Table 3 , Model 4).
Correlation of the MTHFR 677C4T and MTHFR1298A4C polymorphisms with clinical and laboratory data in ZAP-70-negative CLL
The frequencies of the MTHFR 677T and the 1298C alleles were not significantly different between ZAP-70-negative andpositive patients. The progression-free survival was significantly increased by almost a factor of 2 in patients with the 677CC genotype (240 months) compared to those with the 677T allele (120 months, P ¼ 0.046). No significant difference in the progression-free survival was seen for the MTHFR 1298A4C polymorphism, but we noted a trend for longer progression-free survival for patients with the MTHFR 1298AC or CC genotype (240 months) compared with those with MTHFR 1298AA genotype (120 months, P ¼ 0.12). The combined analysis of both MTHFR polymorphisms separated the ZAP-70-negative subgroup in the best way by a significantly longer progressionfree survival for those with MTHFR 677CC and MTHFR 1298AC or CC (240 months) compared to those with MTHFR 677CT or TT and MTHFR 1298AA (120 months, P ¼ 0.037). No significant differences in the progression-free survival were observed in the ZAP-70-positive subgroup.
Increased spontaneous apoptosis in B cells from CLL patients with the MTHFR 677CC and MTHFR1298AC/CC polymorphisms
Finally, we analyzed the association of genotypes with spontaneous apoptosis rates of B cells from CLL patients in vitro. The spontaneous apoptosis rates after 24 h were significantly increased in patients with the MTHFR 677CC genotype vs MTHFR 677CT and MTHFR 677TT genotypes (41, 35 and 25%, respectively, P ¼ 0.045; Figure 3a) . Also, the spontaneous apoptosis rate was significantly decreased in MTHFR 1298AA genotype vs MTHFR 1298AC genotype (29 and 40%, respectively, P ¼ 0.015; Figure 3b ). In summary, B cells from those patients in the favorable risk group with the genotypes 1298AC plus CC and 677CC showed significantly more spontaneous apoptosis than those in the unfavorable risk group. Haplotypes were calculated using the data from 111 patients and 92 controls as described in 'Materials and methods'. Significant linkage between the indicated alleles was found for both cohorts (Po0.001; w 2 test).
Discussion
Recently, several gene polymorphisms have been suggested to correlate with clinical outcome in B-CLL. Saxena et al 34 reported an association of a novel-SNP(À248) G/A, in the 5 0 -UTR of the BAX gene in B-CLL with disease progression and treatment resistance. Recently, we 35 showed an association of the C/C genotype of the 825C/T polymorphism of the G protein b3 gene (GNB3) with a high relapse rate in patients with CLL. Thunberg et al 36 described a 1513A/C polymorphism in the P2X7 receptor gene to be associated with overall survival in patients with CLL. We and others 37, 38 could not confirm the results by Thunberg et al.
Here we demonstrate the influence of the two common MTHFR polymorphisms in the progression of B-CLL.
MTHFR plays a central role in DNA methylation, synthesis and repair. Low enzyme activity may reduce the capacity of DNA methylation, and possibly reduce uracil misincorporation into DNA. Malignancies derived from rapidly proliferating tissues are expected to have an increased requirement for DNA synthesis, and patients with such malignancies could, therefore, be even more endangered by folate deficiency and resultant DNA damage. 11, 39, 40 Recently, it was suggested that polymorphisms at positions 677 and 1298 of the MTHFR gene are associated with reduced susceptibility for acute lymphocytic leukemia. 12 Comparing frequencies of MTHFR genotypes in CLL patients vs healthy controls, no significant differences were observed. Therefore, MTHFR polymorphisms are unlikely to influence the susceptibility to develop CLL. A strong linkage disequilibrium of these two polymorphisms was confirmed here.
When all patients with CLL regardless of stage were analyzed, time from diagnosis to initiation of chemotherapy was virtually independent of MTHFR 677 or MTHFR 1298 genotypes. However, in CLL patients with stage A according to Binet, we found a significantly more aggressive clinical course in patients with MTHFR 677CT or TT genotypes or with MTHFR 1298AA genotypes compared to those with MTHFR 677CC or MTHFR 1298AC or CC genotypes (Figure 1 ). The association of the MTHFR 677T allele with enhanced disease progression is not unexpected as the 677T allele is associated with reduced enzyme activity compared to the CC genotype. However, the finding of an enhanced disease progression in patients with 1298AA genotype appears contraintuitive as the 1298A allele is associated with increased rather than decreased enzyme activity compared to the CC genotype. On the other hand, others showed the lowest MTHFR activity to be associated with the combination of the 677TT and 1298AA genotypes. 18 
Figure 1
Probability of disease progression as indicated by the treatment-free interval. Kaplan-Meier curve compares time periods from diagnosis to initiation of chemotherapy in 74 CLL patients in stage A according to Binet. (a) Progression-free survival curves of patient subgroups defined by the combination of 677CT and 677TT genotypes vs 677CC genotype. (b) Progression-free survival curves of patient subgroups defined by the combination of 1298CC and 1298CA genotypes vs 1298AA genotype. Statistical analysis was performed using the log-rank test. The number of patients are in parentheses.
Figure 2
Association of 677/1298 haplotypes with the treatmentfree interval. Time period to first therapy for 54 CLL patients in stage A according to Binet displaying either the 1298AC or 1298CC genotypes in combination with the 677CC genotypes (dashed line), the 1298AA genotypes in combination with the 677CT or 677TT genotypes (dashed plump line) and the heterozygous group with 677CT plus 1298AC (solid line). Statistical analysis was performed using the logrank test. The number of patients are in parentheses.
In the next step, we performed a haplotype analysis of the two polymorphisms. Patients with the C allele for both polymorphisms have a significant longer progression-free survival than those with 677T allele plus 1298A allele. Because of the borderline course of the heterozygous group (677CT plus 1298AC), we investigated only the two haplotypes without this group for a better discrimination.
After confirming the prognostic value of the combination of CD38 and ZAP-70 in our CLL cohort for patients in Binet stage A, we performed a multivariate analysis to explore the relative value of the MTHFR polymorphisms as independent factors with regard to established prognostic factors, for example, ZAP-70 and CD38. On separate analyses of the MTHFR 677C4T and MTHFR 1298A4C gene polymorphisms, analyses of the 677CT plus TT genotypes and MTHFR 1298AA alone appear to be better prognostic markers than the CD38 status (P ¼ 0.065 and 0.025, respectively). However, the ZAP-70 status was the best independent prognostic factor in the multivariate analysis. In the next step, we investigated MTHFR haplotypes for their prognostic power in the multivariate analysis. The analysis showed that this haplotype is the only independent prognostic marker, excluding CD38 and ZAP-70 status. Notably, only the combination of CD38 and ZAP-70 may be a better independent marker than the combination of the two MTHFR polymorphisms.
Finally, our results showed that the two MTHFR polymorphisms, and especially the MTHFR haplotypes, could predict disease progression in the ZAP-70-negative cohort, but not in the ZAP-70-positive cohort. However, this subgroup analysis is based on 13 patients in each group and needs to be confirmed in a larger patient cohort.
In accordance with the results discussed above, B cells from patients in the favorable risk group with genotypes 1298AC and 677CC showed significantly more spontaneous apoptosis after 24 h in vitro than those from patients belonging to the unfavorable risk group. To the best of our knowledge, this is the first report showing that spontaneous apoptosis in B-CLL cells is associated with or may even depend on MTHFR genotypes. Thus, we show here more than a pure association of MTHFR genotypes with progression of CLL, as these in vitro findings may provide a mechanistic link between MTHFR genotypes and disease progression.
Our data provide some evidence suggesting that disease progression in CLL patients with Binet stage A is significantly influenced by MTHFR genotypes. The fact, that these genetic host factors only play a pivotal role in CLL patients with Binet A is in line with the hypothesis that such genetic polymorphisms mainly influence the course of disease in localized and not advanced stages.
Finally, some limitations of our study must be discussed. The major confinement resides in the limited number of cases that was available for analysis. This becomes especially evident in haplotype analysis and when subgroups are analyzed, for example, ZAP-70-negative patients. Moreover, a common problem of all smaller genetic association studies resides in potential unrecognized selection bias, which cannot be excluded definitively.
Nevertheless, our data generate novel hypotheses regarding the role of MTHFR gene variants in the progression of CLL, which will have to be confirmed in independent studies. This will help to clarify whether especially those associations reported here which just escaped statistical evidence presumably due to limited sample size can be corroborated. It would be of special interest to determine a potential association of MTHFR variants with folate and homocysteine status. Moreover, the pathways determining differences in programmed cell death dependent on MTHFR genotypes should be unravelled. Eventually, these investigations could lead to novel therapeutic regimens including, for example, folate supplementation in patients with unfavorable MTHFR genotypes.
